Hemoglobinopathies are rare disorders of the red blood cells. These diseases result from abnormalities in the hemoglobin molecule. A person is born with a hemoglobinopathy when their genes cause the abnormal molecule to be synthesized and not the normal molecule. In newborns, a carrier screening for hemoglobinopathy and spinal muscular atrophy is available. The patient is then referred to a contracted medical center for evaluation and treatment.
Request Here For PDF Brochure With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/4059
Hemoglobinopathies are inherited disorders of the hemoglobin molecule. Inheritance is the major cause. Although these diseases are rare, they have become more common in central and northern Europe, due to immigration. The diagnosis and treatment of hemoglobinopathy and its complications require a careful review of the literature and consideration of national guidelines. Hemoglobinopathies can lead to a wide range of conditions, including cancer, anemia, and anemia.
Hemoglobinopathy Treatment Drugs Market – Impact of Coronavirus (Covid-19) Pandemic
The pandemic of COVID-19 has significantly augmented demand for several drugs. The correct treatment and management of infection by coronavirus (COVID-19) in patients affected by rare hematological diseases may be challenging due to the rapid spread of the pandemic and limited literature so far, especially in some countries such as U.K, U.S. Italy, Face, Spain, Russia, India and others. Patients with certain hemoglobinopathies are more prone to get infected by coronavirus infection. For instance, in June 2020, according to survey carried out by European Hematology Association (EHA) Annual Congress, many patients with hemoglobinopathies, predominantly those with sickle cell disease, were infected with severe acute respiratory syndrome coronavirus.
The hemoglobinopathy treatment drugs market is estimated to be valued at US$ 3.3 billion in 2020 and is expected to exhibit a CAGR of 8.4% during the forecast period (2020-2027).
Growing prevalence of hemoglobinopathies and new product launch are expected to boost growth of the hemoglobinopathy treatment drugs market
The rising prevalence of hemoglobinopathies such as thalassemia is driving hemoglobinopathy treatment drugs market growth over the forecast period. For instance, according to a report of Pediatric Blood Cancer 2018, alpha thalassemia is the most common single-gene disorder in the world. It is estimated that there are 270 million carriers of mutant globin genes that can potentially cause severe forms of thalassemia. Moreover, 300,000-400,000 severely affected infants are born every year, more than 95% of whom are in Asia, or in the Middle East.
Moreover, increasing product approvals by regulatory bodies is again expected to foster market growth. For instance, in November 2019, Celgene Corporation and Acceleron Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) approved REBLOZYL (luspatercept-aamt) for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.
Hemoglobinopathy Treatment Drugs Market – Restraints
Unsuccessful clinical trials for the treatment of sickle cell anemia is projected to restrict the hemoglobinopathy treatment drugs market growth. For instance, in August 2019, Pfizer Inc. announced that the Phase III Rivipansel pivotal study, to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease, failed to achieve its primary or key secondary efficacy endpoints for pediatric patients.
Get Sample Report With Latest Covid19 Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/4059
Moreover, unavailability of permanent cure for hemoglobinopathy disorders is again projected to hinder the market growth. Current treatment available only focus on reducing symptoms of the disorders and the only reliable treatment available is bone marrow transplant, which is a very complex and costly procedure. Moreover, it is also associated with some side effects.
Hemoglobinopathy Treatment Drugs Market – Regional Analysis
North America is estimated to account for the largest share in the hemoglobinopathy treatment drugs market in 2020, due to growing FDA approvals for product launch in North America region. For instance, in May 2020, CRISPR Therapeutics and Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX001, an investigational, autologous, gene-edited hematopoietic stem cell therapy, for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
Furthermore, the growing prevalence of hemoglobinopathies in Asia Pacific, Middle East, and Africa region is projected to foster the hemoglobinopathy treatment drugs market growth in the near future. For instance, in 2018, according to a report of Pediatric Blood Cancer 2018, the frequency of alpha thalassemia alleles in genes is 5-10% in the Mediterranean basin, 20-30% in portions of West Africa, and as high as 60-80% in parts of Saudi Arabia, India, Thailand, Papua New Guinea, and Melanesia. In Thailand, which has a population of 62 million people, around 7,000 infants are born each year with hemoglobin H disease.
Hemoglobinopathy Treatment Drugs Market – Competitive Landscape
Key players engaged in the hemoglobinopathy treatment drugs market include Bristol-Myers Squibb Company, GlycoMimetics Inc., Pfizer Inc., Anthera Pharmaceuticals Inc., Eli Lilly and Company, Mast Therapeutics, Daiichi Sankyo Company Ltd., Novartis International AG, Bluebird Bio Inc., HemaQuest Pharmaceuticals Inc., Emmaus Medical Inc., Prolong Pharmaceuticals, Merck & Co., Inc., Medunik USA Inc., Sangamo Therapeutics, Inc., Global Blood Therapeutics, Alnylam Pharmaceuticals, and Acceleron Pharma, Inc.
Direct Purchase This Report with Access of full Information @ https://www.coherentmarketinsights.com/insight/buy-now/4059
Reasons to Purchase This Report
• Current and future of Hemoglobinopathy Treatment Drugs Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Disease Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- COVID-19 Impact on Market
- Pre-COVID 19 Situation
- Post-COVID 19 Situation
- Market Trends
- Epidemiology
- Regulatory Scenario
- Reimbursement Scenario
- New Product Launches/Approvals
- Mergers & Acquisitions
- Porter’s Analysis
- PEST Analysis
- Market Dynamics
- Global Hemoglobinopathy Treatment Drugs Market COVID-19 Impact Analysis
-
- Pre-COVID 19 Situation
- Post-COVID 19 Situation
- Strategies
-
- Global Hemoglobinopathy Treatment Drugs Market, By Drug Type, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Analgesics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- ACE Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Hydroxyurea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- Global Hemoglobinopathy Treatment Drugs Market, By Disease Type, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Thalassemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Sickle Cell Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Other Hb Variants Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- Global Hemoglobinopathy Treatment Drugs Market, By Distribution Channel, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- Global Hemoglobinopathy Treatment Drugs Market, By Region, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, By Region, 2017 – 2027
- Regional Trends
- North America
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Disease Type, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- North Africa
- Central Africa
- South Africa
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Introduction
View Press Release: https://www.coherentmarketinsights.com/press-release/hemoglobinopathy-treatment-drugs-market-3316
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837